HTG is a precision medicine company harnessing the power of RNA to drive translational research, clinical diagnostics and therapeutic development. HTG’s proprietary RNA technologies are designed to help better understand disease and treatment options for patients and to unlock a disruptive approach to drug discovery.

Category:
Videos

HTG Therapeutices Introduction

HTG Therapeutics is focused on utilizing its innovative technology platforms to create an entirely new generation of drug discovery tools aimed at developing therapeutic candidates with superior efficacy and safety profiles - transforming the process across a broad range of disease areas including oncology, immunology, diabetes, and rare diseases, among others.

Category:
Videos

A comparison of gene expression technologies in clinical applications

In this webcast Dr. Kerry Culm-Merdek of OncXerna and Dr. Marian Navratil of HTG Molecular review a cross-platform performance comparison study between RNA-Seq and HTG's translational research profiling panel, the HTG EdgeSeq Precision Immuno-Oncology Panel.

Category:
Videos

HTG EdgeSeq Panels Empowers Precision Medicine

Learn about the benefits of the HTG EdgeSeq technology and how HTG is advancing precision medicine all starting with one 5 µl FFPE tissue. Get more answers from less sample.

Category:
Videos

LinkedIn Webinar: Virtual Podium 2020, Session 6, Precision Medicine

HTG joined Virtual Podium 2020 on May 1 for their Session 6 discussion on Precision Medicine. Dr. James Cooley, HTG's Sr. Marketing Manager, Assays, presented on our new end-user bioinformatics pipeline for patient stratification in precision medicine with the HTG EdgeSeq Reveal software data analysis tool.

Category:
Videos

HTG EdgeSeq technology and RNA-Seq technology

ASCO 2020 poster on platform comparison between HTG EdgeSeq technology and RNA-Seq narrated by HTG's Sr. Manager, Assay Development, Heather Gustafson.

Category:
Videos

The molecular landscape of oral neoplasias and the risk of progression to malignancy

ASCO 2019 Clinical Science Symposium, Dr. William from M.D. Anderson and Hospital BP in Sao Paulo Brazil presented an interesting body of work around the molecular landscape of oral neoplasias and the risk of progression to malignancy.

Category:
Videos

HTG EdgeSeq System Workflow

HTG Molecular's EdgeSeq system is a fully automated sample and library preparation method and platform for sequencing-based gene expression.

Watch Now

Category:
Videos

Products:
HTG EdgeSeq System

HTG EdgeSeq Chemistry – Sample and Library Preparation

Narrated overview of the HTG EdgeSeq system sample and library preparation steps.

Watch Now

Category:
Videos

Products:
HTG EdgeSeq System

Webinars

Presenters : Dr. Leonie Frauenfeld and Sebastian Streich

Institution: University of Tubingen, Germany

Originally aired on: Wednesday, May 24, 2023

Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements

by Dr. Leonie Frauenfeld

Diffuse large B-cell lymphoma (DLBCL) with aberrant coexpression of CD10+BCL6+MUM1+ (DLBCL-AE), classified as germinal center B cell (GCB) type by the Hans algorithm (HA), was genetically characterized. To capture the complexity of DLBCL-AE, collaborators used an integrated approach that included two different gene expression profiling (GEP) systems (HTG, EdgeSeq DLBCL Cell of Origin Assay and NanoString, Lymph2Cx assay), fluorescence in situ hybridization, targeted gene sequencing, and copy number (CN) arrays. The collaborators found that DLBCL-AE are genetically heterogeneous and enriched in cases with IRF4 alterations. The correlation between the 2 different GEP assays was very good, no discordant cases were classified as GCB or ABC, 5 unclassifiable cases in Lymph2Cx were classified as either ABC or GCB in HTG EdgeSeq. The LBCL-IRF4 in adults has many similarities to the pediatric counterpart, this entity is described as a definitive entity in both the International Consensus Classification of Mature Lymphoid Neoplasms and the 5th edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Prevalence of IRF4 rearrangement in large B-cell lymphomas of the Waldeyer's ring in adults

by Sebastian Streich

Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma in adults. Recent studies have suggested new subtypes of large B-cell lymphoma, based on genetic and molecular alterations, including the large B-cell lymphoma with IRF4-rearrangement (LBCL-IRF4), which are defined as a definite entity in the International Consensus Classification of Mature Lymphoid Neoplasms and in the 5th edition of the WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. We used fluorescence in situ hybridization (FISH), gene expression profiling (GEP) (HTG, EdgeSeq DLBCL Cell of Origin Assay), and next-generation sequencing (NGS) to comprehensively characterize LBCLs located in Waldeyer’s ring in adult patients and to identify cases of LBCL-IRF4.

Category:
Webinars

Transcriptome-Wide GEP Profiles Reveal Different Patterns Between Synovial Sarcomas and Morphologic Mimickers

Presenters : Dr. Sabrina Borchert

Institution: University Hispital Essen, Germany

Originally aired on: Friday, March 3, 2023

The ability to tailor treatment for individual cancer patients is one of the most pivotal goals of oncology precision medicine. To accomplish this, scientists must translate the biology driving each patient’s tumor in order to assess the risk of morbidity and mortality and identify an optimized plan for the best possible outcomes. In this webinar, Dr. Sabrina Borchert will discuss how she and her team tested the robustness and the reliability of a novel quantitative nuclease protection assay (HTG Transcriptome Panel) for patients suffering from spindle cell and synovial sarcoma. She will further describe how the investigators were able to compare genetically determined tumor entities with morphologic mimickers by applying a genome-wide transcriptional analysis. The full-text peer-reviewed publication can be accessed HERE.

Key Learning Objectives

Gain insight into recent advances in RNA-based gene expression profiling

Identify opportunities to improve outcomes for patients suffering from spindle cell and synovial sarcoma

Review the utility of ultra-efficient GEP in real-world applications, such as oncological research

Understand the benefits of novel profiling technologies compared to traditional methods

Category:
Webinars

More Data From Less Material: Ultra-Efficient Transcriptome Profiling

Presenters : Dr. Sabrina Borchert and Andriana Gialeli

Institution: University Hispital Essen, Germany

Originally aired on: Wednesday, February 8, 2023

Translational Research Group at University Hospital Essen receives Qualified Service Provider certificate from HTG and presents two case studies.

"Nuclease-protection-based Gene Expression Profiling and its Application in Translational Tumor Researh" by Dr. Sabrina Borchert

"MicroRNA Profiling of Cerebrospinal Fluid from Preterm Infants Following Perinatal Brain Injury" by Andriana Gialeli

Category:
Webinars

The Role of RNA Profiling in Drug Discovery and Analysis

Presenter: Dr. Robert Spitale

Institution: University of California, Irvine

Originally aired on: Tuesday, December 13, 2022

The webinar featured a presentation from KOL, Dr. Robert Spitale, PhD, University of California – Irvine, who discussed how RNA molecules can be used to understand the pharmaceutical drug effects on humans and help develop them towards more successful clinical use. The HTG Therapeutics team dove into the value of early pre-clinical insights that can be collected through their proprietary and comprehensive transcriptome-informed drug discovery platform.

View External Link

Category:
Webinars

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

Presenter: Dr. Pierre Saintigny

Institution: University Claude Bernard Lyon

Originally aired on: Friday, November 4, 2022

The webinar featured Dr. Pierre Saintigny, Professor of Medicine at University Claude Bernard Lyon 1 and a medical oncologist at the Léon Bérard (CLB) Cancer Center

The ability to tailor treatment for individual cancer patients is one of the most pivotal goals of oncology precision medicine. To accomplish this, scientists must translate the biology driving each patient’s tumor in order to assess the risk of morbidity and mortality and identify an optimized plan for the best possible outcomes. In this webinar Professor Saintigny will discuss how his team developed a reliable and stable scoring system using gene expression profiling to identify immunologically active tumors from patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who can benefit from immunotherapy.

View External Link

Category:
Webinars

Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes

Presenter: Dr. Robert Spitale and Dr. Debrah Thompson

Institution: University of California – Irvine and HTG

Originally aired on: Wednesday, July 27, 2022

On July 27, 2022 HTG hosted a key opinion leader (KOL) webinar on “Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes”.

The webinar featured a presentation from KOL, Dr. Robert Spitale, PhD, University of California – Irvine, who discussed the use of RNA-based platform technologies in drug discovery. The HTG Therapeutics team introduced their proprietary transcriptome-informed drug discovery platform as the cornerstone of their differentiated and de-risked approach to small molecule drug discovery.

View External Link

Category:
Webinars

Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research

Presenter: Dr. Peter Ansell and Dr. Marian Navratil

Institution: Abbvie and HTG

Originally aired on: Thursday, June 23, 2022

The ability to predict the cancer treatment for each individual patient is one of the most pivotal goals of oncology precision medicine. To accomplish this, scientists must gain an improved understanding of the biology driving each patient’s tumor. Differential gene expression can identify which molecular pathways are aberrantly regulated and thereby inform which treatment will be most effective.

Often such studies are limited due to sample size or quality issues, long turnaround times for lab processing, difficulty in deciphering the data, and insufficient reproducibility for an eventual companion diagnostic test.

In this talk, Dr. Peter Ansell from AbbVie discusses how his team overcame some of these challenges using novel technologies available on the market. He presents a case study to demonstrate the utility of such technologies and their benefits over traditional gene expression profiling methods. Lastly, discusses the future of biomarker-based treatments for oncology patients and the impact HTG is making in the field.

Key Learning Objectives

Overview of advances in RNA-based gene expression profiling
Introduction to ultra-efficient gene expression profiling (GEP) technology and its importance in maximizing reliable information while conserving precious samples
Evaluation of the utility of ultra-efficient GEP in real-world applications, such as for clinical and preclinical oncology research
Discussion about the benefits of novel profiling technologies compared to traditional methods

View External Link

Category:
Webinars

Vascular Damage, Thromboinflammation, Plasmablast Activation, T-Cell Dysregulation and Pathological Histocytic Response in Pulmonary Draining Lymph Nodes of COVID-19

Presenter: Dr. Alexander Tzankov and Selina Gaertner

Institution: Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland and HTG

Originally aired on: Tuesday, March 29, 2022

The presentation highlights how HTG EdgeSeq technology was used to shed light on on gene expression profiles of challenging FFPE tissue samples collected during autopsy of patients who passed away from COVID-19.

Autopsy studies of COVID-19 casualties can shed light on the disease, it’s effect on human organism, and potential treatments. Researchers conducted a comprehensive study of autopsy samples collected from March to April 2020, to better understand the pathophysiology and gene expression regulation. With use of HTG EdgeSeq technology they were able to uncover unexpected gene expression profiles such as overexpression of genes related to platelet/vascular functions and angiogenesis and downregulation of genes related to T-/NK functions, leukocyte adhesion and migration. These findings can lead to development of more targeted treatment options in the future.

View External Link

Category:
Webinars

HTG Transcriptome Panel revealed fusion type dependent biomarkers, impacting overall survival in Synovial Sarcoma

Presenters: Dr. Hans-Ulrich Schildhaus and Selina Gaertner

Institution: Institute of Pathology, University Hospital Essen and HTG

Originally aired on: Tuesday, February 11, 2022

The presentation introduces HTG EdgeSeq technology and HTG Transcriptome Panel (HTP) as well as highlights how HTP was used to reveal fusion type biomarkers impacting overall survival in synovial sarcoma patients.

Synovial Sarcomas (SyS) represent a group of soft tissue sarcomas which affect patients at a wide age range, including adolescents and young adults. Most SyS are clinically aggressive, many patients suffer from local relapse and even from distant metastases. Sys is paradigm for gene fusion events which until recently was difficult to investigate. However, with the new developments in transcriptome profiling technologies, especially with extraction-free transcriptome profiling tools, the researchers identified differentially expressed genes that are linked to different translocation types. The identified biomarkers offer new opportunities for improved diagnostics for aggressive synovial sarcoma patients.

View External Link

Category:
Webinars

Breast Cancer Recurrence Risk Classification and Molecular Subtyping Using HTG EdgeSeq Technology

Presenter: Dr. Jose Antonio López Guerrero

Institution: Instituto Valenciano de Oncología (IVO)

Originally aired on: Tuesday, November 9, 2021

The presentation highlights how HTG EdgeSeq technology can be used to determine recurrence risk and molecular subtyping of early-stage HR+ and HER-2 breast cancer.

Breast Cancer is a heterogeneous group of different disease subtypes, each with its own biological and clinical characteristics. The traditional clinical and pathological methods of estimating the probability of breast cancer recurrence use patient age, tumor size, tumor grade , and number of involved axillary lymph nodes. Estrogen and progesterone receptor expression used to be evaluated using immunohistochemistry. However, with the current advances in transcriptome profiling technologies the researchers were able to use HTG Edgeseq Precision Immuno-Oncology Panel and HTG EdgeSeq Pan B-Cell Lymphoma Panel to shed new light on the disease and possible treatment options.

View External Link

Category:
Webinars

Fusion Type Dependent Biomarkers Impacting Overall Survival in Synovial Sarcoma, Revealed by HTG Transcriptome Profiling

Presenter: Dr. Hans-Ulrich Schildhaus

Institution: Institute of Pathology, University Hospital Essen and West German Cancer Center Essen in Germany

Originally aired on: Wednesday, November 10, 2021

Synovial Sarcomas (SyS) represent a group of soft tissue sarcomas which affect patients at a wide age range, including adolescents and young adults. Most SyS are clinically aggressive, many patients suffer from local relapse and even from distant metastases. Sys is paradigm for gene fusion events which until recently was difficult to investigate. However, with the new developments in transcriptome profiling technologies the researchers were able to explore how comprehensive gene expression analyses can help to define SyS and SyS subgroups, determine how SyS as a group differ from other sarcomas, and to identify differentially expressed genes that are relevant to the disease.

View External Link

Category:
Webinars

NATURE SHORTCAST: Utilizing GEP to Integrate Biomarker Data and Illuminate Complex Biology

Originally aired on: Tuesday, September 18, 2018

This presentation will highlight our newly released HTG EdgeSeq Precision Immuno-Oncology Panel that was specifically developed to answer a wide range of translational questions tied to immuno-oncology and known drug resistance pathways.

Watch Now

Category:
Webinars

MicroRNAs in CSF as prodromal biomarkers for Huntington’s disease

Originally aired on: Tuesday, May 29, 2018

The Myers lab has studied microRNAs (miRNA) in Huntington disease (HD) brain, plasma and cerebrospinal fluid (CSF). In a study to assess the potential of miRNAs as biomarkers for disease, we found increased miRNA levels were detected in CSF for carriers of the HD trinucleotide repeat expansion mutation up to twenty years before expected disease onset. Levels increased as proximity to onset decreased suggesting miRNAs may serve as effective biomarkers for prodromal disease long before disease manifestation.

Watch Now

Category:
Webinars

Integrated Molecular Profiling of Genitourinary Tumors: Applications for Personalized Radiotherapy

Originally aired on: Wednesday, June 28, 2017

In this webcast, Dr. Omar Mian, from Cleveland Clinic Foundation, will:

Review the basic principles of personalized radiotherapy
Describe the clinical unmet need for improved molecular biomarkers
Understand the rationale for tumor profiling in terms of genotype / phenotype relationships
Recognize the value of integrated approaches exploring genetic, structural, and epigenetic alterations
Discuss the value of cell free DNA as a biomarker in non-invasive detection

Watch Now

Category:
Webinars

Products:
HTG EdgeSeq Oncology Biomarker Panel

Evaluation of a novel microRNA Whole Transcriptome Assay

Originally aired on: Wednesday, April 12, 2017

In this webcast, the performance of the HTG EdgeSeq miRNA Whole Transcriptome Assay (WTA) is evaluated using the samples and methods from the miRQC study.

Watch Now

Category:
Webinars

Products:
HTG EdgeSeq miRNA Whole Transcriptome Assay
miRNA

FFPE Tissue and the HTG EdgeSeq Oncology Biomarker Panel

Originally aired on: Tuesday, September 20, 2016

HTG EdgeSeq Oncology Biomarker Panel covers 2,560 genes. This pilot study examined different amounts of tissue input from 3 colorectal and 2 breast tumors down to 3.1 mm2, representing ¼ the recommended input.

Watch Now

Category:
Webinars

Products:
HTG EdgeSeq Oncology Biomarker Panel

New tools for Biomarker Discovery Promise Personalized Treatment for Rheumatoid Arthritis

Originally aired on: Tuesday, July 26, 2016

This webinar outlined an ongoing project to develop personalized treatment strategies for rheumatoid arthritis patients using miRNA profiling.

Watch Now

Category:
Webinars

Products:
HTG EdgeSeq miRNA Whole Transcriptome Assay
miRNA

Expression-Based Profiling of Challenging FFPE Tumor Samples

Originally aired on: Thursday, May 19, 2016

This webinar focused on recent advances in gene expression profiling of challenging formalin-fixed, paraffin-embedded tissue samples for cancer research and clinical practice. The presentation covered studies in non-small cell lung cancer and pancreatic cancer.

Watch Now

Category:
Webinars

Products:
HTG EdgeSeq Oncology Biomarker Panel

NGS-Based miRNA Profiling to Develop Signatures of Potential Clinical Applications

Originally aired on: Wednesday, December 2, 2015

This webinar discusses potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.

Watch Now

Category:
Webinars

Products:
HTG EdgeSeq miRNA Whole Transcriptome Assay
miRNA

HTG Transcriptomics

HTG EdgeSeq RUO Panels

Resources

Categories

Filter by Products

Case Studies

HTG EdgeSeq Immune Response Cytokine Release Syndrome with CAR T cell therapy

HTG EdgeSeq miRNA WTA Diabetes Case Study

HTG EdgeSeq miRNA WTA Osteoclasts Case Study

HTG EdgeSeq Immune Response Rheumatoid Arthritis Case Study

HTG EdgeSeq Immune Response Inflammatory Bowel Disease Case Study

HTG EdgeSeq Immune Response Systemic Sclerosis Case Study

HTG EdgeSeq miRNA WTA Breast Case Study

HTG EdgeSeq miRNA WTA UV Case Study

HTG EdgeSeq miRNA Whole Transcriptome Assay identifies miRNA expression signatures in biofluids aiding in forensic identification

HTG EdgeSeq Immune Response Panel COVID-19 SARS-CoV-2 Case Study

Brochures

HTG EdgeSeq System Workflow Brochure

Comprehensive Tumor Profiling Brochure

Gene Lists

HTG Transcriptome Panel Probe List

HTG EdgeSeq DLBCL Cell of Origin Assay Gene List

HTG EdgeSeq miRNA Whole Transcriptome Assay Cross-Species Gene List

HTG EdgeSeq Oncology Biomarker Panel Gene List

Select and download available HTG EdgeSeq Oncology Biomarker Panel genes

HTG EdgeSeq Oncology Biomarker Panel Gene List

Annotated Gene List HTG EdgeSeq Precision Immuno-Oncology Panel

HTG EdgeSeq Precision Immuno-Oncology Panel Gene List

HTG EdgeSeq Immune Response Panel Gene List

HTG EdgeSeq Immune Response Panel Annotated Gene List

HTG EdgeSeq Mouse mRNA Tumor Response Panel Gene List

Product Sheets

HTG Transcriptome Panel Product Sheet

HTG EdgeSeq Immuno-Oncology Assay Product Sheet

HTG EdgeSeq miRNA Whole Transcriptome Assay Product Sheet

HTG EdgeSeq Oncology Biomarker Panel Product Sheet

VERI/O Laboratory Services Product Sheet

HTG EdgeSeq Precision Immuno-Oncology Panel Product Sheet

HTG EdgeSeq System Product Sheet

HTG EdgeSeq Immune Response Panel Product Sheet

HTG EdgeSeq Pan B-Cell Lymphoma Panel Product Sheet

HTG EdgeSeq Reveal Oncology Signatures Immune, Stroma and TME

HTG EdgeSeq Mouse mRNA Tumor Response Panel Product Sheet

HTG EdgeSeq Reveal Product Sheet

HTG EdgeSeq Reveal Oncology Signatures Immunophenotyping

HTG EdgeSeq Reveal Immunophenotyping Signatures

HTG EdgeSeq Reveal Immune, Stroma, and TME Signatures

Tech Notes

Tech Note: HTG Transcriptome Panel Gene Expression Profiling Data Demonstrate High Correlation Using Illumina and Thermo Fisher Sequencing Platforms

Tech Note: Application of HTG Transcriptome Panel for Targeted Gene Expression Profiling in COVID-19 Cases

Tech Note: Immunophenotyping Lymphocytes in Tumors

Tech Note: Measuring Immune Checkpoint Genes from FFPE Tissue

Tech Note: Assessing Tumor Inflammation

Tech Note: Epithelial Mesenchymal Transition in Immuno-Oncology

Tech Note: Benchmark Study of HTG Transcriptome Panel and NanoString nCounter PanCancer Immune Profiling and Custom Panels

Safety Data Sheets

Lysis Buffer A Safety Data Sheet

Probe Solution(s) Safety Data Sheets

DNase Enzyme and Buffer Safety Data Sheet

Nuclease Protection Probes Safety Data Sheet

RNA Extraction-Free Buffer Safety Data Sheet

100x Process Control Ladder Oligo Pool

Biofluids Plasma Lysis Buffer Safety Data Sheet

Chemiluminescent Substrate A Safety Data Sheet

Chemiluminescent Substrate B Safety Data Sheet

Denaturation Oil Safety Data Sheet

Detection Enzyme Buffer + Mixture Safety Data Sheet

Detection Linker Solution DL Safety Data Sheet

Detection Probe Safety Data Sheet

HTG EdgeSeq Sequencing Tag Safety Data Sheet

Lysis Buffer Safety Data Sheet

Neutralization Solution Safety Data Sheet

Programming Linker Solution PL Safety Data Sheet

Proteinase K Safety Data Sheet

Red Imaging Oil Safety Data Sheet

S1 Digestion Buffer Safety Data Sheet

S1 Enzyme + Buffer Mixture Safety Data Sheet

S1 Stop Solution Safety Data Sheet

Termination Solution Safety Data Sheet

Wash Buffer Solution Safety Data Sheet